Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 3, 2008, Pages 583-586

  Herzmann, Christian ^a   Cuthbertson, Z ^b   Fosdick, L ^c   Fisher, M ^d   Nelson, M ^e   Perry, N ^d   Law, M ^f   Wand, H ^f   Janossy, G ^b   Johnson, M A ^b   Youle, M ^b  

^a Vivantes Auguste Viktoria Klinikum   (Germany)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF BRIGHTON   (United Kingdom)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

CD4 cell count; HIV viral load; Immunomodulation; Long term follow up; UK Vanguard

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 2; PLACEBO; VIRUS RNA;

ANUS CARCINOMA; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EXPOSURE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; FOLLOW UP; HEPATITIS; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LONG TERM CARE; LOW DRUG DOSE; LUNG TUBERCULOSIS; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREATITIS; PNEUMOCYSTIS PNEUMONIA; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL; SALMONELLOSIS; SQUAMOUS CELL CARCINOMA;

ANTI-RETROVIRAL AGENTS; AREA UNDER CURVE; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; RNA, VIRAL; VIRAL LOAD;

EID: 49649127208     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn238     Document Type: Article

References (9)

1. Vento S, Cainelli F, Temesgen Z. Interleukin-2 therapy and CD4+ T cells in HIV-1 infection. Lancet 2006; 367: 93-5.
2. Emery S, Abrams DI, Cooper DA et al., ESPRIT Study Group. The evaluation of subcutaneous proleukin (interleukin-2) in a randomised international trial: Rationale, design, and methods of ESPRIT. Control Clin Trials 2002; 23: 198-220.
3. Arduino RC, Nannini EC, Rodriguez-Barradas M et al. Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT) Vanguard Group; ESPRIT Executive Committee. CD4 cell response to 3 doses of subcutaneous interleukin 2: Meta-analysis of 3 Vanguard studies. Clin Infect Dis 2004; 39: 115-22. Epub 14 June 2004.
4. Youle M, Emery S, Fisher M et al. A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: The UK-Vanguard Study. PLoS Clin Trials 2006; 1: E3. Epub 19 May 2006. Erratum in: PLoS Clin Trials 2007; 2: E23.
5. Durier C, Capitant C, Lascaux AS et al. Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials). Acquir Immune Defic Syndr 2007; 21: 1887-97.
6. Vogler MA, Teppler H, Gelman R et al., AIDS Clinical Trials Group 248 Study Team. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248). J Acquir Immune Defic Syndr 2004; 36: 576-87.
7. Venet A, Gougeon ML, Hamonic S et al., and ANRS 119 Interstart group. Intermittent interleukin-2 therapy induces the expansion of naïve and central memory CD4 T cells and has no impact on HIV-specific T-cell responses in ART-naïve HIV-infected patients: immunological Substudy of the ANRS 119 Interstart Trial. 14th Conference on Retroviruses and Opportunistic Infections 2007. Abstract 395, session 77. http://www.retroconference.org/2007/Abstracts/ 29807.htm (15 April 2008, date last accessed).
8. Henry K, Katzenstein D, Cherng DW et al. A5102 Study Team of the AIDS Clinical Trials Group. A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: Results of ACTG A5102. J Acquir Immune Defic Syndr 2006; 42: 140-8.
9. Angus B, Lampe F, Tambussi G et al., and TILT trial steering committee. The TILT trial - a pilot trial of ART interruption with and without the use of interleukin-2. 14th Conference on Retroviruses and Opportunistic Infections 2007. Abstract 477, session 86. http://www.retroconference.org/2007/Abstracts/28153.htm (15 April 2008, date last accessed).